Abstract
This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.
| Original language | English (US) |
|---|---|
| Title of host publication | Evidence-Based Dermatology: Third Edition |
| Publisher | Wiley Blackwell |
| Pages | 231-240 |
| Number of pages | 10 |
| ISBN (Print) | 9781118357606, 9781118357675 |
| DOIs | |
| State | Published - Aug 11 2014 |
| Externally published | Yes |
Fingerprint
Keywords
- Antisense therapy
- Cytotoxic chemotherapeutic agents
- Lentigo maligna melanoma (LMM)
- Metastatic malignant melanoma
- Primary cutaneous melanoma
- Sentinel lymph-node biopsy
ASJC Scopus subject areas
- Medicine(all)
Cite this
Treatment of Cutaneous Melanoma. / Johnson, Mary Ann N; Armstrong, April W.
Evidence-Based Dermatology: Third Edition. Wiley Blackwell, 2014. p. 231-240.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Treatment of Cutaneous Melanoma
AU - Johnson, Mary Ann N
AU - Armstrong, April W.
PY - 2014/8/11
Y1 - 2014/8/11
N2 - This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.
AB - This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.
KW - Antisense therapy
KW - Cytotoxic chemotherapeutic agents
KW - Lentigo maligna melanoma (LMM)
KW - Metastatic malignant melanoma
KW - Primary cutaneous melanoma
KW - Sentinel lymph-node biopsy
UR - http://www.scopus.com/inward/record.url?scp=84926400451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926400451&partnerID=8YFLogxK
U2 - 10.1002/9781118357606.ch31
DO - 10.1002/9781118357606.ch31
M3 - Chapter
AN - SCOPUS:84926400451
SN - 9781118357606
SN - 9781118357675
SP - 231
EP - 240
BT - Evidence-Based Dermatology: Third Edition
PB - Wiley Blackwell
ER -